

# Deepak Nitrite

Estimate change

TP change

Rating change



**CMP: INR1,736**

**TP: INR1,450 (-16%)**

**Sell**

## Stable operating performance amid persistent macro headwinds

### Operating performance beats estimate

- Deepak Nitrite (DN) reported a healthy operating performance, with EBIT growing 18% YoY to INR3.1b, led by 20% YoY EBIT growth in the Phenolic segment. This growth was driven by strong pricing gains and stable plant operations, while Advanced Intermediate's EBIT declined 25% YoY.
- While near-term performance may continue to see some pressure amid persistent industry-wide challenges and evolving geopolitical developments, the impact on overall performance is likely to remain limited, supported by continuous process refinements and cost optimization initiatives.
- Factoring in the better-than-expected margin in 4QFY26, we increase our FY27/FY29 estimates by 7%/9% and expect a CAGR of 11%/19%/23% in revenue/EBITDA/PAT over FY26-28. **We value the stock at 24x FY28E EPS to arrive at our TP of INR1,450. Reiterate Sell.**

### The intermediate segment continues to face margin headwinds

- DN's 4Q revenue declined 3% YoY to INR21.2b (est. in line), primarily due to a 7% YoY decline in phenolics to INR14.3b, while advanced intermediates' revenue grew 8% YoY to INR7.1b.
- Gross margin came in at 34.9% (up 430bp YoY), while EBITDAM stood at 17.7% (up 320bp YoY). Employee costs as a % of sales stood at 5.2% (vs. 4.7% in 4QFY25), while other expenses stood at 12% (vs. 11.4% in 4QFY25).
- EBITDA grew 19% YoY to INR3.7b (our est. INR2.5b), and EBIT for Phenolics grew 20% YoY, while EBIT for advanced intermediates declined 25%.
- EBIT margin for advanced intermediates contracted 210bp, while EBIT margins for Phenolic expanded 440bp YoY to 20%.
- Adjusted PAT stood at INR2.2b (est. of INR1.5b), up 8% YoY.
- In FY26, DN's revenue/EBITDA/adj. PAT declined 5%/10%/20% to INR78.9b/INR9.8b/INR5.6b.
- CFO stood at INR5.4b as of Mar'26 compared to INR6.2b as of Mar'25.

### Highlights from the management commentary

- **Advanced Intermediates:** The nitrogen and hydrogenation plants have already been commissioned and are operating at the desired productivity and efficiency levels. However, in 4Q, the company faced technical issues at its nitric acid plant, resulting in ~45% utilization, following which the company had to procure the balance of nitric acid requirements from the market to ensure uninterrupted production and meet customer demand.
- **Polycarbonate:** DN is making steady progress on its polycarbonate project, with rapid dismantling of its German plant at Stade. The shipment of equipment to India is already underway, alongside ongoing infrastructure development and contractor mobilization in India. Additionally, the company has signed a long-term agreement with Linde plc for a dedicated on-site HyCO (hydrogen and carbon monoxide) plant to ensure a reliable raw material supply, with commissioning targeted for Jun'28 in line with the project timeline.

Bloomberg	DN IN
Equity Shares (m)	136
M.Cap.(INRb)/(USD\$)	236.8 / 2.5
52-Week Range (INR)	2174 / 1280
1, 6, 12 Rel. Per (%)	16/10/-12
12M Avg Val (INR M)	363

### Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	78.9	88.7	96.4
EBITDA	9.8	11.9	14.0
PAT	5.6	7.2	8.4
EPS (INR)	41.0	52.7	61.8
EPS Gr. (%)	-19.7	28.3	17.4
BV/Sh. (INR)	427.9	470.8	521.1

### Ratios

Net D:E	0.2	0.5	0.9
RoE (%)	10.0	11.7	12.5
RoCE (%)	8.2	8.2	7.4
Payout (%)	18.6	18.6	18.6

### Valuations

P/E (x)	42.6	33.2	28.3
P/BV (x)	4.1	3.7	3.4
EV/EBITDA (x)	25.6	22.7	21.7
Div. Yield (%)	0.4	0.6	0.7
FCF Yield (%)	-2.8	-7.5	-12.8

### Shareholding Pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	49.3	49.3	49.3
DII	23.5	23.2	23.2
FII	6.2	6.1	6.7
Others	21.0	21.4	20.9

FII includes depository receipts

- **Product development:** The company has commenced commercial-scale validation batches for 6-7 new products, including fluorinated molecules, with initial customer feedback remaining positive. Management expects regular commercial production to begin from 3Q onwards, aligned with export customers' CY26 requirements, while commercialization of Methyl isobutyl ketone (MIBK) and Methyl Isobutyl Carbinol (MIBC) remains broadly on track.
- **Raw material:** At the end of Feb'26, inventory levels of critical feedstocks remained elevated due to opportunistic procurement of raw materials during periods of price correction. This strategy has served the company well, and management anticipates maintaining a reasonable inventory of feedstock at favorable prices through the end of 2QFY27.

### Valuation and view

- The global chemical industry continues to face a challenging operating environment characterized by persistent global challenges, uneven recovery in demand, and the West Asia crisis, leading to disruption in established supply chains, challenges to logistics, and volatility of crude oil prices.
- The company's focus on continuous process refinements and cost optimization initiatives is expected to drive operational performance and fortify its competitive positioning. Further commercialization of new products, along with the commercialization of MIBK/MIBC projects by early 2QFY26, is also expected to drive earnings growth.
- Factoring in the better-than-expected margin in 4QFY26, we raise our FY27/FY29 estimates by 7%/9% and expect a CAGR of 11%/19%/23% in revenue/EBITDA/PAT over FY26-28. **We value the stock at 24x FY28E EPS to arrive at our TP of INR1,450. Reiterate Sell.**

### Consolidated - Quarterly Snapshot


Y/E March	FY25				FY26				(INR m)			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FY25	FY26	FY26 4QE	Var. (%)
<b>Gross Sales</b>	<b>21,668</b>	<b>20,320</b>	<b>19,034</b>	<b>21,797</b>	<b>18,899</b>	<b>19,019</b>	<b>19,750</b>	<b>21,203</b>	<b>82,819</b>	<b>78,871</b>	<b>21,518</b>	<b>-1%</b>
YoY Change (%)	22.5	14.3	-5.3	2.5	-12.8	-6.4	3.8	-2.7	7.8	-4.8	-1.3	
<b>Total Expenditure</b>	<b>18,577</b>	<b>17,345</b>	<b>17,349</b>	<b>18,631</b>	<b>17,003</b>	<b>16,976</b>	<b>17,641</b>	<b>17,443</b>	<b>71,901</b>	<b>69,064</b>	<b>19,045</b>	
<b>Gross Margin (%)</b>	<b>30.8%</b>	<b>32.0%</b>	<b>26.8%</b>	<b>30.6%</b>	<b>28.0%</b>	<b>27.6%</b>	<b>27.8%</b>	<b>34.9%</b>	<b>30.1%</b>	<b>29.7%</b>	<b>29.0%</b>	
<b>EBITDA</b>	<b>3,092</b>	<b>2,975</b>	<b>1,685</b>	<b>3,166</b>	<b>1,896</b>	<b>2,043</b>	<b>2,109</b>	<b>3,760</b>	<b>10,918</b>	<b>9,807</b>	<b>2,473</b>	<b>52%</b>
Margin (%)	14.3	14.6	8.9	14.5	10.0	10.7	10.7	17.7	13.2	12.4	11.5	
Depreciation	475	485	482	513	513	533	576	626	1,954	2,246	590	
Interest	58	63	61	93	81	79	110	189	275	460	115	
Other Income	188	213	210	228	246	200	85	69	839	599	200	
<b>PBT</b>	<b>2,748</b>	<b>2,640</b>	<b>1,352</b>	<b>2,788</b>	<b>1,547</b>	<b>1,630</b>	<b>1,380</b>	<b>3,014</b>	<b>9,528</b>	<b>7,571</b>	<b>1,968</b>	
Tax	723	698	371	762	425	443	382	815	2,554	2,064	495	
Rate (%)	26.3	26.4	27.4	27.3	27.5	27.2	27.7	27.1	26.8	27.3	25.2	
<b>Reported PAT</b>	<b>2,025</b>	<b>1,942</b>	<b>981</b>	<b>2,025</b>	<b>1,122</b>	<b>1,187</b>	<b>998</b>	<b>2,197</b>	<b>6,974</b>	<b>5,504</b>	<b>1,473</b>	<b>49%</b>
<b>Adj PAT</b>	<b>2,025</b>	<b>1,942</b>	<b>981</b>	<b>2,025</b>	<b>1,122</b>	<b>1,187</b>	<b>1,091</b>	<b>2,197</b>	<b>6,974</b>	<b>5,598</b>	<b>1,473</b>	<b>49%</b>
YoY Change (%)	35.1	-5.3	-51.4	3.4	-44.6	-38.9	11.2	8.5	-7.3	-19.7	-27.3	
Margin (%)	9.3	9.6	5.2	9.3	5.9	6.2	5.5	10.4	8.4	7.1	6.8	

### Exhibit 1: Change in estimates

Particulars	Actual/ Revised		Previous		Change (%)	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Revenue (INR m)	88,748	96,356	88,063	95,602	1%	1%
EBITDA (INR m)	11,941	13,958	11,005	12,930	9%	8%
PAT (INR m)	7,185	8,433	6,691	7,719	7%	9%
EPS (INR)	52.7	61.8	49.1	56.6	7%	9%


## 4QFY26 in charts

**Exhibit 2: Revenue mix trend**




Source: Company, MOFSL

**Exhibit 3: EBIT mix trend**




Source: Company, MOFSL

**Exhibit 4: Sales declined 3% YoY**




Source: Company, MOFSL

**Exhibit 5: Margin trends**




Source: Company, MOFSL

**Exhibit 6: EBITDA grew 19%**




Source: Company, MOFSL

**Exhibit 7: Reported PAT trend**




Source: Company, MOFSL

**Exhibit 8: Revenue from AI grew 8% YoY**




Source: Company, MOFSL

**Exhibit 9: AI EBITM trend**




Source: Company, MOFSL

**Exhibit 10: Revenue from DPL declined 7% YoY...**



Source: Company, MOFSL

**Exhibit 11: ...with EBIT margin at 20%**



Source: Company, MOFSL



## Highlights from the management commentary

### Operational highlights:

- Against a backdrop of continued volatility, marked by severe disruption in crude-linked supply chains, pricing pressure, and geopolitical events, DN has delivered a strong performance.
- Volume stability, favorable pricing trends, plant fungibility by pivoting towards products, customers, and markets showcasing better demand have supported the overall momentum.
- The company witnessed steady domestic demand, coupled with increasing preference for local, reliable sourcing amid global supply chain disruptions, positively contributing to the business momentum.
- Domestic demand in India continued to be stable across most end-user industries.
- Domestic business contribution remained high at ~86% of revenue, while exports contributed ~14%

### Advanced Intermediates

- The Advanced Intermediates business witnessed strong performance driven by steady domestic demand, with a focus on high-demand applications, effectively offsetting slower export momentum caused by global supply chain disruptions
- While proactive procurement strategies helped partly mitigate the geopolitical headwinds, the current pricing environment for critical feedstocks remains volatile
- Enhanced profitability was a direct outcome of product mix optimization, better sales price relative to RM costs, and deeper integration, ensuring raw material self-sufficiency
- A deepened integration continues to provide a competitive edge through an increased raw material self-sufficiency and reduced supply chain volatility
- nitrogen and hydrogenation, those plants are already commissioned, and they are operating with the right productivity and efficiency
- In 4Q, the company faced technical issues at its nitric acid plant, resulting in operations running at ~45% utilization. To avoid disruptions in production and meet customer demand, the company procured the balance of nitric acid requirements from the market. Once the operations are normalized, the company is targeting an EBITA of ~INR90b

### Phenolic

- The Phenolics business delivered robust performance backed by strong pricing gains.
- The volume was stable despite geopolitical conflict in the Middle East, impacting the timely supply of critical feedstocks.
- Performance was supported by stable plant operations and recovery in downstream demand from polymer and industrial applications.
- Ongoing process optimization and debottlenecking initiatives are scaling the operational capacity to align with consistent domestic demand.
- DN continues to be the largest capacity and can service the market for all specifications for IPA
- India continues to have a positive dynamic for phenol in terms of supply and demand

### Polycarbonate:

- Plant dismantling at Stade, Germany, is progressing rapidly, with shipment of equipment to India already underway

- Infrastructure activities, including contractor mobilization in India, are currently underway
- Ordering multiple pieces of equipment in India, including boilers, commenced
- The company has signed a long-term agreement with Praxair India (Linde) to set up a dedicated HyCO plant. This will be an on-site facility to ensure a reliable supply of critical raw materials, improving operational efficiency and supply chain security. Commissioning targeted for June 2028, in line with DCTL's Polycarbonate project timeline
- Management stated that the company's total announced project outlay stands at ~INR110b to be funded through a 60:40 debt-equity mix. The company has already begun infusing equity, while bank financing has been tied up and is expected to be drawn down once the required equity contribution milestones are met.

### Outlook

- Recent developments in key export markets provide grounds for cautious optimism.
- The management is sharpening its focus on innovation, new product development, and expanding the company's presence across geographies and chemistries.
- Outlook: The near-term industry conditions are expected to remain influenced by geopolitical developments. Chinese supply dynamics, US tariff policies, and feedstock volatility.
- Management highlighted that Deepak Nitrite continues to operate with a high degree of productivity and efficiency, supporting healthy margins. The company also expects 1Q performance to improve sequentially over 4Q and remain ahead of last year's 1Q levels.
- Management expects tightening regulations in China around the production, storage, and transportation of certain key chemistries to support higher demand and improved profitability for nitrogen-based products.

### New project

- The company reported steady progress in its multi-purpose agrochemical intermediates and MIBC projects, both of which are scheduled to be commissioned in 2QFY27.
- The company has commenced manufacturing commercial-scale validation batches for 6-7 new products, including fluorinated molecules. These batches have either already been supplied to customers with positive initial feedback or are currently in transit to customers.
- Management expects regularized commercial production to begin from 3Q onwards, aligning with export customers' CY26 requirements. The company added that it remains broadly on track with its commercialization plans and continues to engage closely with customers, who have appreciated the transparency amid the current volatility.

### Others


- FY2025-26 was a challenging year for the global chemical industry, marked by sustained pricing pressure across chemical value chains and continued disruption in global trade flows
- During FY26, the company undertook a comprehensive cost optimization program focused on improving product yields, enhancing energy efficiency, and increasing manufacturing productivity through digital and technological initiatives. Management noted that geopolitical and macroeconomic

uncertainties could continue to create near-term volatility across global markets.

- The company continues to engage regularly with customers to maintain and strengthen both wallet share and market share.
- The company entered the end of February with elevated inventory levels of critical feedstocks, having opportunistically procured raw materials during periods of price correction, and this has held out quite well for the company. The management anticipates that the company has a reasonable inventory of feedstock at enviable prices till the end of 2QFY27


## Financial story in charts

**Exhibit 12: Revenue contribution from Phenol to remain higher...**




Source: MOFSL

**Exhibit 13: ...with a focus on the domestic market as a play on import substitution**




Source: Company, MOFSL

**Exhibit 14: Segmental EBIT breakdown of DN**




Source: Company, MOFSL

**Exhibit 15: EBIT margin**




Source: Company, MOFSL

**Exhibit 16: EBITDA margin to normalize from FY22 levels**



Source: Company, MOFSL

**Exhibit 17: Expect ~23% PAT CAGR over FY26-28**



Source: Company, MOFSL

## Financials and valuations

### Consolidated - Income Statement

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>Total Income from Operations</b>	<b>43,598</b>	<b>68,022</b>	<b>79,721</b>	<b>76,818</b>	<b>82,819</b>	<b>78,871</b>	<b>88,748</b>	<b>96,356</b>
Change (%)	3.1	56.0	17.2	-3.6	7.8	-4.8	12.5	8.6
Gross Margin (%)	48.1	39.5	32.9	31.8	30.1	29.7	29.8	30.8
<b>EBITDA</b>	<b>12,470</b>	<b>16,036</b>	<b>12,894</b>	<b>11,233</b>	<b>10,918</b>	<b>9,807</b>	<b>11,941</b>	<b>13,958</b>
Margin (%)	28.6	23.6	16.2	14.6	13.2	12.4	13.5	14.5
Depreciation	1,526	1,777	1,663	1,657	1,954	2,246	2,611	2,723
<b>EBIT</b>	<b>10,944</b>	<b>14,259</b>	<b>11,231</b>	<b>9,576</b>	<b>8,964</b>	<b>7,561</b>	<b>9,330</b>	<b>11,235</b>
Int. and Finance Charges	742	340	248	118	275	460	349	640
Other Income	215	426	476	761	839	599	621	674
<b>PBT bef. EO Exp.</b>	<b>10,417</b>	<b>14,345</b>	<b>11,459</b>	<b>10,219</b>	<b>9,528</b>	<b>7,699</b>	<b>9,601</b>	<b>11,269</b>
<b>PBT after EO Exp.</b>	<b>10,417</b>	<b>14,345</b>	<b>11,459</b>	<b>11,017</b>	<b>9,528</b>	<b>7,571</b>	<b>9,601</b>	<b>11,269</b>
Total Tax	2,659	3,678	2,939	2,908	2,554	2,064	2,417	2,836
Tax Rate (%)	25.5	25.6	25.6	26.4	26.8	27.3	25.2	25.2
<b>Reported PAT</b>	<b>7,758</b>	<b>10,666</b>	<b>8,520</b>	<b>8,109</b>	<b>6,974</b>	<b>5,505</b>	<b>7,185</b>	<b>8,433</b>
<b>Adjusted PAT</b>	<b>7,758</b>	<b>10,666</b>	<b>8,520</b>	<b>7,522</b>	<b>6,974</b>	<b>5,598</b>	<b>7,185</b>	<b>8,433</b>
Change (%)	27.0	37.5	-20.1	-11.7	-7.3	-19.7	28.3	17.4
Margin (%)	17.8	15.7	10.7	9.8	8.4	7.1	8.1	8.8

### Consolidated - Balance Sheet

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	273	273	273	273	273	273	273	273
Total Reserves	23,194	33,112	40,627	47,693	53,614	58,096	63,945	70,810
<b>Net Worth</b>	<b>23,467</b>	<b>33,384</b>	<b>40,900</b>	<b>47,966</b>	<b>53,887</b>	<b>58,368</b>	<b>64,218</b>	<b>71,083</b>
Minority Interest	-	-	-	261	360	325	325	325
Total Loans	5,775	3,007	545	2,170	11,705	15,278	38,462	60,000
Deferred Tax Liabilities	1,078	1,229	1,566	1,736	2,128	2,467	2,467	2,467
<b>Capital Employed</b>	<b>30,320</b>	<b>37,620</b>	<b>43,011</b>	<b>52,133</b>	<b>68,080</b>	<b>76,438</b>	<b>1,05,471</b>	<b>1,33,875</b>
Gross Block	22,441	25,263	26,523	31,690	35,262	45,632	47,632	49,632
Less: Accum. Deprn.	3,666	5,443	7,106	8,763	10,717	12,963	15,574	18,298
<b>Net Fixed Assets</b>	<b>18,774</b>	<b>19,820</b>	<b>19,416</b>	<b>22,927</b>	<b>24,546</b>	<b>32,669</b>	<b>32,057</b>	<b>31,334</b>
Goodwill on Consolidation	-	-	-	-	27	27	27	27
Capital WIP	2,068	1,037	3,008	7,735	16,491	18,282	41,650	80,018
<b>Total Investments</b>	<b>1,893</b>	<b>4,390</b>	<b>3,794</b>	<b>1,219</b>	<b>5,109</b>	<b>2,133</b>	<b>2,133</b>	<b>2,133</b>
<b>Curr. Assets, Loans, and Adv.</b>	<b>12,868</b>	<b>19,057</b>	<b>25,069</b>	<b>29,081</b>	<b>31,004</b>	<b>33,696</b>	<b>41,201</b>	<b>32,878</b>
Inventory	3,827	5,846	8,931	7,599	9,264	8,623	9,590	10,288
Account Receivables	7,563	11,291	13,095	12,984	12,738	15,055	16,941	18,393
Cash and Bank Balance	334	418	400	4,655	4,066	2,690	6,425	-4,756
Loans and Advances	1,144	1,503	2,644	3,844	4,937	7,328	8,246	8,953
<b>Curr. Liability and Prov.</b>	<b>5,283</b>	<b>6,684</b>	<b>8,277</b>	<b>8,829</b>	<b>9,097</b>	<b>10,369</b>	<b>11,597</b>	<b>12,514</b>
Account Payables	4,367	5,117	6,618	5,823	5,217	5,341	5,940	6,372
Other Current Liabilities	640	1,272	1,216	2,476	3,259	4,277	4,812	5,225
Provisions	276	296	443	531	620	751	845	917
<b>Net Current Assets</b>	<b>7,585</b>	<b>12,373</b>	<b>16,792</b>	<b>20,252</b>	<b>21,908</b>	<b>23,328</b>	<b>29,604</b>	<b>20,363</b>
<b>Appl. of Funds</b>	<b>30,320</b>	<b>37,620</b>	<b>43,011</b>	<b>52,133</b>	<b>68,080</b>	<b>76,438</b>	<b>1,05,471</b>	<b>1,33,875</b>

## Financials and valuations

### Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>Basic (INR)</b>								
<b>EPS</b>	<b>56.9</b>	<b>78.2</b>	<b>62.5</b>	<b>55.1</b>	<b>51.1</b>	<b>41.0</b>	<b>52.7</b>	<b>61.8</b>
EPS Growth (%)	27%	37%	-20%	-12%	-7%	-20%	28%	17%
Cash EPS	68.1	91.2	74.7	67.3	65.5	57.5	71.8	81.8
BV/Share	172.0	244.8	299.9	351.7	395.1	427.9	470.8	521.1
DPS	5.5	7.0	7.5	7.5	7.5	7.5	9.8	11.5
Payout (%)	9.7	9.0	12.0	12.6	14.7	18.6	18.6	18.6
<b>Valuation (x)</b>								
P/E	30.7	22.4	28.0	31.7	34.2	42.6	33.2	28.3
Cash P/E	25.7	19.2	23.4	26.0	26.7	30.4	24.3	21.4
P/BV	10.2	7.1	5.8	5.0	4.4	4.1	3.7	3.4
EV/Sales	5.6	3.5	3.0	3.1	3.0	3.2	3.0	3.1
EV/EBITDA	19.6	15.0	18.5	21.0	22.5	25.6	22.7	21.7
Dividend Yield (%)	0.3	0.4	0.4	0.4	0.4	0.4	0.6	0.7
FCF per share	57.8	46.8	21.3	8.0	-36.2	-48.2	-130.2	-223.7
<b>Return Ratios (%)</b>								
RoE	39.6	37.5	22.9	16.9	13.7	10.0	11.7	12.5
RoCE	29.1	32.1	21.6	16.0	11.9	8.2	8.2	7.4
RoIC	32.1	36.7	24.7	19.0	16.2	11.5	12.9	15.0
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	2.4	3.5	4.1	3.6	3.5	2.8	2.7	3.0
Asset Turnover (x)	1.4	1.8	1.9	1.5	1.2	1.0	0.8	0.7
Inventory (Days)	32	31	41	36	41	40	39	39
Debtor (Days)	63	61	60	62	56	70	70	70
Creditor (Days)	37	27	30	28	23	25	24	24
<b>Leverage Ratio (x)</b>								
Current Ratio	2.4	2.9	3.0	3.3	3.4	3.2	3.6	2.6
Interest Coverage Ratio	14.7	41.9	45.3	80.9	32.6	16.4	26.7	17.6
Net Debt/Equity ratio	0.2	0.1	0.0	-0.1	0.1	0.2	0.5	0.9

### Consolidated - Cash Flow Statement

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	10,417	14,345	11,459	11,017	9,528	7,571	9,601	11,269
Depreciation	1,526	1,777	1,663	1,657	1,954	2,246	2,611	2,723
Others	852	295	63	-509	-285	187	349	640
Direct Taxes Paid	-2,365	-3,535	-2,600	-2,665	-2,152	-1,887	-2,417	-2,836
(Inc.)/Dec. in WC	-412	-4,643	-4,085	-720	-2,798	-2,728	-2,542	-1,940
<b>CF from Operations</b>	<b>10,019</b>	<b>8,239</b>	<b>6,499</b>	<b>8,781</b>	<b>6,247</b>	<b>5,390</b>	<b>7,604</b>	<b>9,856</b>
(Inc.)/Dec. in FA	-2,140	-1,862	-3,599	-7,685	-11,191	-11,968	-25,368	-40,368
<b>Free Cash Flow</b>	<b>7,879</b>	<b>6,377</b>	<b>2,900</b>	<b>1,096</b>	<b>-4,944</b>	<b>-6,579</b>	<b>-17,764</b>	<b>-30,512</b>
Change in Investments	-1,854	-2,401	816	427	-4,059	3,146	0	0
Others	33	22	22	40	337	2,135	0	0
<b>CF from Investments</b>	<b>-3,961</b>	<b>-4,241</b>	<b>-2,761</b>	<b>-7,218</b>	<b>-14,913</b>	<b>-6,687</b>	<b>-25,368</b>	<b>-40,368</b>
Inc./(Dec.) in Debt	-5,246	-2,812	-2,523	1,625	9,277	3,495	23,183	21,538
Interest Paid	-736	-320	-233	-98	-194	-384	-349	-640
Dividend Paid	-4	-750	-955	-1,023	-1,023	-1,023	-1,335	-1,567
Others	-5	24	120	-68	-100	-155	0	0
<b>CF from Fin. Activity</b>	<b>-5,990</b>	<b>-3,858</b>	<b>-3,591</b>	<b>435</b>	<b>8,062</b>	<b>1,934</b>	<b>21,499</b>	<b>19,331</b>
<b>Inc./Dec. in Cash</b>	<b>68</b>	<b>139</b>	<b>148</b>	<b>1,998</b>	<b>-605</b>	<b>636</b>	<b>3,735</b>	<b>-11,181</b>
Opening Balance	22	90	229	377	2,380	1,795	2,431	6,166
<b>Closing Balance</b>	<b>90</b>	<b>229</b>	<b>377</b>	<b>2,380</b>	<b>1,795</b>	<b>2,431</b>	<b>6,166</b>	<b>-5,015</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://qalaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motalal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motalal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motalaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motalaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motalaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motalaloswal.com
Mr. Ajay Menon	022 40548083	am@motalaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motalaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motalaloswal.com

Registration details of group entities.: Motalal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motalal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motalaloswal.com. In case of grievances for any of the services rendered by Motalal Oswal Financial Services Limited (MOFSL) write to grievances@motalaloswal.com, for DP to dpgrievances@motalaloswal.com.